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Abstract
Background: Clostridium difficile (CD) is a leading cause of diarrhoea among hospitalized patients. The objective of
this study was to evaluate the rate, the optimal diagnostic work-up, and outcome of CD infections (CDI) in Internal
Medicine (IM) wards in Italy.
Methods: PRACTICE is an observational prospective study, involving 40 IM Units and evaluating all consecutive
patients hospitalized during a 4-month period. CDI were defined in case of diarrhoea when both enzyme
immunoassay for GDH, and test for A/B toxin were positive. Patients with CDI were followed-up for recurrences for
4 weeks after the end of therapy.
Results: Among the 10,780 patients observed, 103 (0.96 %) showed CDI, at admission or during hospitalization. A
positive history for CD, antibiotics in the previous 4 weeks, recent hospitalization, female gender and age were
significantly associated with CDI (multivariable analysis). In-hospital mortality was 16.5 % in CD group vs 6.7 % in
No-CD group (p < 0.001), whereas median length of hospital stay was 16 (IQR = 13) vs 8 (IQR = 8) days (p < 0.001)
among patients with or without CDI, respectively. Rate of CD recurrences was 14.6 %. As a post-hoc evaluation, 23
out of 34 GDH+/Tox- samples were toxin positive, when analysed by molecular method (a real-time PCR assay). The
overall CD incidence rate was 5.3/10,000 patient-days.
Conclusions: Our results confirm the severity of CDI in medical wards, showing high in-hospital mortality, prolonged
hospitalization and frequent short-term recurrences. Further, our survey supports a 2–3 step algorithm for CD diagnosis:
EIA for detecting GDH, A and B toxin, followed by a molecular method in case of toxin-negative samples.
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Background
Clostridium difficile (CD) is a Gram-positive, spore-forming,
exotoxin-producing anaerobic bacillus responsible for a
range of clinical conditions, from asymptomatic infection to
slight diarrhoea, pseudomembranous colitis, toxic megaco-
lon and bowel perforation [1].
Clinical suspicion and appropriate and timely laboratory
diagnosis are crucial for the treatment and prevention of
Clostridium difficile infection (CDI). Although a number
of laboratory tests are available for the diagnosis of CDI,
including direct detection of CD products [2], the optimal
diagnostic strategy is still debated. A two- or three-stage
algorithm may improve the sensitivity of CDI diagnosis
[2, 3], but a great heterogeneity exists among laborator-
ies as for implementation of these procedures which
are affected by availability of resources and expertise.
Elderly patients are at the highest risk of infection, espe-
cially if they are hospitalized or residents in nursing care
home. Suggested risk factors for developing CDI include
prior antibiotic use, acid suppressive agents [4, 5], previ-
ous CDI [6], malignancies, gastrointestinal disorders [7]
and inflammatory bowel diseases [8]. Recurrent CDI is as-
sociated with significant morbidity, mortality and add-
itional need of healthcare resources. Recurrences generally
occur within 4 weeks from the end of antibiotic therapy,
with reported incidence of 20–30 % [9, 10].
Rates of CDI have been increasing since 2000 in both
North America and Europe [11], with the highest inci-
dence rates in elderly patients [12]. This increased preva-
lence of CDI has prompted the development of national
infection prevention programs. According to a survey
published in 2014, around half of European countries had
issued a national guideline for CDI prevention [13]. The
United Kingdom requires public reporting of CDI cases
by individual hospitals, while in Germany severe cases of
CDI must be reported to government health authorities.
Further, different options of CDI surveillance for acute
care hospitals have been tested across Europe [14]. In
Italy, no nationwide program for surveillance of CDI has
been implemented to date, and there is a lack of reliable
data on the epidemiology of CDI at national level. Pub-
lished information on the burden of CDI in Italy comes
from a single hospital or a small group of hospitals, is
often retrospective and the reported incidence is highly
variable [15–19]. This variability may be related in part to
heterogeneity in diagnostic methods used from one la-
boratory to the next. Therefore, a nationwide prospective
survey is needed to better evaluate the incidence of CDI
among Italian hospitals, also applying a standardized diag-
nostic method, and especially in medical wards which ac-
count for the majority of reported cases [17, 20].
To address this need, the Italian Scientific Society of
Hospital Internal Medicine (FADOI), in cooperation with
the Italian Association of Clinical Microbiologists (AMCLI),
planned, coordinated and implemented the prospective
national surveillance program “FADOI-PRACTICE”, to
determine the incidence of CDI in Internal Medicine
units in Italy and collect data on patient outcomes, re-
currences, and CDI risk factors.
Methods
Patients and methods
The FADOI-PRACTICE is an observational, prospective,
multicentre study involving 40 hospitals in Italy, aimed
at evaluating the incidence of CDI (new cases developed
at least 3 days after admission to hospital/10,000 patients-
days) and risk factors for CD in Internal Medicine units
(IMU). Moreover, the study allowed to evaluate the preva-
lence of CDI in IMUs (cases of diarrhoea at hospital ad-
mission/study population), the length of hospital stay and
all-cause in-hospital mortality in the groups of patients
with and without CDI. Among patients with CDI, the
percentage of CD recurrences, either as in-hospital
cases and during post-discharge follow-up (within 4 weeks
after the end of CDI therapy), as well as the rate of re-
hospitalization and all-cause mortality during follow-up
were also assessed. Recurrences were defined as episodes
occurring after resolution of symptoms (i.e. 3 days free
from diarrhoea) and completion of the cycle of therapy for
CDI [1, 2].
The study enrolled all consecutive patients hospitalized
in an IMU for any cause during a 4-month period
(October 2013 - January 2014). Internal Medicine units
were selected with the aim to be representative of this set-
ting on a nationwide basis, by considering geographical
distribution, characteristics of the hospital (category, num-
ber of beds etc.), and clinical care services. At admission
to the IMU information on risk factors for CDI was
collected for each patient: age, gender, renal dysfunction
(severe: creatinine clearance [CrCl] <30 mL/min; moder-
ate: 30 ≤CrCl ≤ 65 mL/min), inflammatory bowel disease
(IBD), immunosuppression, use of antibiotics, use of
proton pump inhibitors, H2-receptor antagonists or other
antacids, use of laxatives, use of statins, parenteral nutri-
tion, prolonged bed rest (of at least 30 days within
3 months prior to hospitalization), hospitalization (of at
least 3-day duration), patient from nursing care home/
post-acute care or rehabilitation facilities, previous CDI
(within 12 months). Data were recorded on a study-
specific electronic case report form, based on contents of
the hospital charts. CDI were identified testing all samples
of diarrhoea (defined as at least three consecutive episodes
selected according to Bristol Stool Chart ≥5) through the
same diagnostic test: enzyme immunoassay (EIA) for
detecting CD glutamate dehydrogenase (GDH), and A
and B toxin (C. Diff Quik Chek® and Tox A/B Quik Chek®,
AlereTM). CD diagnosis was considered confirmed if both
tests were positive.
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For patients with diagnosis of CD, information on
signs and symptoms of infection, specific treatments,
healthcare procedures, complications, recurrences and
all-cause mortality was collected. All CDI patients were
evaluated during their hospital stay, and a phone follow-
up was made 4 weeks after the end of antibiotic therapy
for CDI to evaluate recurrences, survival and possible
re-hospitalizations (Fig. 1).
Each participating centre received the approval for
the study by the local Ethics Committee, and informed
consent has been obtained from each enrolled patient.
As a post-hoc central lab evaluation, a real-time Poly-
merase Chain Reaction (PCR) assay (Xpert® C. difficile,
Cepheid) was used to evaluate both GDH+/Tox + and
GDH+/Tox- samples previously assessed by EIA. This is
an in vitro, 45-min real-time PCR assay that provides
qualitative detection of toxinogenic strains. The primers
and probes in the Xpert C. difficile assay detect sequence
targets in the genes for Toxin B (tcdB), Binary Toxin
(cdt), and tcdC (delection in the toxin A/B negative
regulator gene). All stool samples were inoculated on
Brucella 5 % SB plate. The cultures from specimens with
discordant results between the screening test and the
real-time PCR, were re-tested by an alternate EIA method
(ImmunoCard® Toxins A&B, Meridian).
C. difficile strains were typed using capillary-gel
electrophoresis-based PCR-ribotyping according to Indra
et al. [21]. Ribotypes were determined by submitting data
to the free WEBRIBO database (http://webribo.ages.at) of
the Austrian Agency for Health and Food Safety (AGES).
Statistical analysis
The following common descriptive statistics were calcu-
lated: mean with standard deviation (SD) or median with
interquartile range (IQR) for continuous variables and
absolute and relative frequencies for categorical variables.
For continuous variables, statistical comparisons were made
using unpaired t-test or the analogous non-parametric
Wilcoxon Rank Sum test whenever departure from nor-
mality distribution was detected by the Shapiro-Wilk
test. The Chi-square test or Fisher’s exact test, if deemed
more appropriate, were used to analyze categorical vari-
ables. Incidence rates were expressed as number of cases/
10,000 person-day and reported with 2-sided 95 % Confi-
dence Intervals computed using the Mid-P exact approach
based on a Poisson distribution, while 2-sided 95 % Confi-
dence Intervals of prevalence rates were computed using
the Mid-P exact approach based on a binomial distribu-
tion. Multivariable logistic regression analysis was carried
out to evaluate the possible relationship between the
occurrence of CDI and the following independent vari-
ables: previous CDI (within 12 months); antibiotic use
in the previous 4 weeks; previous hospitalization (within
3 months); age (10-year increase); gender; nursing home
residents (yes or no); bed resting for at least 30 days; use
of proton pump inhibitors; parenteral nutrition (yes or
no). These covariates were selected a priori on the basis of
their clinical plausibility, and following the general rule of
thumb that states that the ratio between the overall num-
ber of events and the number of explanatory variables
should be at least 10 in order to minimize the risk of
Admission to Internal Medicine
Diarrhea YES
Bristol Stool Chart ≥ 5
Diarrhea 
NO
Both tests POS At least one test NEG
• Collection of informed consent
• Collection of risk factors
Collected data on the 
discharge
Collected data on the 
discharge
Collected data on the 
discharge
FOLLOW-UP
4 weeks after the end of
antibiotic therapy for CDI
• GDH test
• Toxins A and B test 
Collected data on the 
management of infection
Fig. 1 Flow-chart of the study
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overfitting. Results are reported as adjusted Odds Ra-
tios with associated 2-sided 95 % Confidence Intervals.
Differences are considered statistical significant for two-
tailed p-values less than 0.05. The Procedure Logistic of
SAS software version 9.4 was used for the multivariable
statistical analysis.
Results
A total of 10,780 patients have been enrolled in the
study, with homogenous geographic distribution in Italy.
Of these, 5.3 % (95 % CI: 4.9 %–5.7 %) experienced diar-
rhoea and 0.96 % (95 % CI: 0.78–1.15 %) had diarrhoea
caused by CDI (N = 103). Symptoms were present in 54
patients at the time of hospital admission (prevalence:
0.52 %, 95 % CI: 0.39–0.67 %). The overall incidence of
CDI in the study setting was 4.4/10,000 patient-days
(95 % CI: 3.28–5.81). Twenty-nine centers registered at
least one case of CDI during the enrolment period, with
an average number of 3.5 ± 3.3 CDI patients per center.
One center was associated with 18 cases, which was much
higher than the other enrolment sites (Table 1).
Patients with CDI were older and more frequently fe-
male. More than one-third were in-patients, coming from
nursing home (19.4 %), or already hospitalized in other
units of the same hospital (17.5 %). Moreover, 58.3 % of
patients with CDI had a hospitalization in the previous
3 months vs only 23.2 % of patients without CDI (p <
0.0001). Overall, 85 % of patients had healthcare-
associated CDI (i.e. recent previous hospitalization or
nursing home residents or onset of diarrhoea 3 days or
more after admission to hospital). A large percentage of
CDI patients had a history of prolonged bed rest (40.8 %),
and 12.6 % of patients had history of CDI in the previous
12 months (Table 2).
About three out of four patients with CDI (70.6 %)
had an antibiotic treatment within 4 weeks before diar-
rhoea vs only 26.6 % in the group without CD, and the
majority had been treated with a cephalosporin (24.3 %),
quinolone (21.9 %) or penicillin (15.8 %). A higher per-
centage of patients with CDI had mild or severe renal
failure (43.7 %) vs. 31.2 % in the group of No-CDI
(Table 2).
Multivariable analysis (Fig. 2) demonstrated that previ-
ous CDI was the strongest predictor of CDI [OR adjusted
13.30, 95 % CI 6.07–27.72], followed by prior antibiotic
treatment [OR adjusted 2.94, 95%CI 1.65–5.37], prior
hospitalization [OR adjusted 2.88, 95 % CI 1.60–5.28], fe-
male gender [OR adjusted 2.28, 95%CI 1.27–4.30] and age
(10-year increase) [OR adjusted 1.37, 95 % CI 1.06–1.83].
Treatment with proton pump inhibitors, nursing home
residency, prolonged bed rest and parenteral nutrition did
not show significant association, although approaching
statistical significance for the first two variables.
In patients with CDI, the therapy of choice was vanco-
mycin (42.8 %), while metronidazole was used in 34 % of
patients. In some cases, both treatments were used in
the same patient, in combination (11.6 %) or in sequence
(11.6 %). Mean duration of CD treatment was 13 days.
Probiotics were prescribed in 19.6 % of CDI patients.
Concerning major outcomes, CDI patients showed a
doubled length of hospital stay with a median of 16
(IQR = 13) days vs 8 (IQR = 8) days in No-CDI (p < 0.001)
and a greater percentage of in-hospital mortality (crude
estimates: 16.5 % vs 6.7 %, p < 0.001). At least one recur-
rence within 4 weeks after conclusion of CDI treatment
was observed in 14.6 % of patients with 66 % of recur-
rences occurred in the first 2 weeks of follow-up. Re-
hospitalizations during follow-up was 19.8 % and the
overall mortality (in-hospital + post-discharge) was 25.2 %.
The post-hoc central lab evaluation showed that CDI
was confirmed by molecular method (real-time PCR assay)
in 97.3 % of the GDH+/Tox + samples. On the other hand,
the PCR assay detected positive samples for the toxin in 23
out 34 (67.6 %) cases which were GDH+/Tox- by EIA.
By adding incident cases within this subgroup, CDI in-
cidence rate was estimated to be 5.3/10.000 patient-days
(4.09–6.88).
We identified 26 different ribotypes of C. difficile among
the 70 strains that were subjected to ribotyping. The pre-
dominant ribotype was 018 (24.3 %), followed by 356/607
(15.6 %), 027 (10 %), 078 (7.1 %) and 126 (5.6 %) (Fig. 3).
Ribotype 356/607 is identified as 356 or 607 by the
University of Leeds database (UK) and the Austrian
Agency for Health and Food Safety (AGES) database,
respectively [22]. One cluster of infection related to
ribotype 018 was detected in the centre with the highest
number of CDI cases (see Table 1). In-hospital mortality
rates related to specific CD ribotypes were 11.7, 9.0,
14.3 and 0 % for 018–356/607–027 and 078 ribotypes,
respectively.
Discussion
Our results confirm that CDI are a not negligible find-
ing (incidence: 5.3/10,000 patient-days) among patients
Table 1 Distribution of cases of CDI (n = 103) in the participating
Centers. At least one case of CDI occurred in 29 Centers; no cases
of CDI were detected in 11 Centers
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Table 2 Baseline characteristics of patients with or without Clostridium difficile infection (CDI). Figures are expressed as number of
cases (%) unless otherwise stated. SD = standard deviation. Bed resting = at least 30 days of bed rest within 3 months prior to






Age (years, mean ± SD) 80.5 ± 11.0 74.7 ± 14.8 <0.0001
Gender (female) 69 (67.0) 5349 (50.1) 0.0006
Coming from <0.0001
Home 65 (63.1) 8926 (83.6)
Nursing-home 20 (19.4) 598 (5.6)
Another hospital unit 18 (17.5) 1110 (10.4)
Not assessed 0 43 (0.4)
Previous hospitalization 60 (58.3) 2477 (23.2) <0.0001
Bed resting 42 (40.8) 1474 (13.8) <0.0001
Previous CDI 13 (12.6) 64 (0.6) <0.0001
Antibiotics treatment (within 4 weeks before) 73 (70.6) 2840 (26.6) <0.0001
Proton pump inhibitors 75 (72.8) 6193 (58.0) 0.0024
H2-receptor antagonists 1 (1.0) 278 (2.6) 0.3009
Other antacids 4 (3.9) 171 (1.6) 0.0626
Prolonged use of laxatives 9 (8.7) 1014 (9.5) 0.7912
Statins treatment 19 (18.4) 1804 (16.9) 0.6841
Comorbidity – at least 5 37 (35.6) 3459 (32.4) 0.6582
Immunodepression 43 (41.7) 3801 (35.6) 0.1984
Renal failure 0.0055
Mild 30 (29.1) 2530 (23.7)
Severe 15 (14.6) 801 (7.5)
No 58 (56.3) 7346 (68.8)
Inflammatory bowel disease 2 (1.9) 107 (1.0) 0.3232
Parenteral nutrition 5 (4.9) 214 (2.0) 0.0413
0,33 1,0 3,3 10                    33                    100
Fig. 2 Multivariable analysis to evaluate factors potentially associated with CD infection. Odds Ratios were mutually adjusted for the other variables
presented in the Figure. Bars represent the 95 % Confidence Intervals
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hospitalized in IMU in Italy. Although direct compari-
son with previously published Italian data (reporting in-
cidence rates from 0.3 to 22.3/10,000 patient-days) is
difficult due to heterogeneity of study designs, timing
of evaluation, and settings, our estimate of incidence
rate is within the range reported for Italy in two recently
published European surveys [16, 19]. In our survey, CDI
accounted for 1 out of 5 cases of diarrhoea among inpa-
tients. When both incident and prevalent cases are con-
sidered, around 1 % of all patients hospitalized in Italian
IMU had diagnosis of CDI (around 1.5 million patients
are admitted to IMU in Italy per year). Finally, healthcare-
associated CDI (recent previous hospitalization/nursing
home residents/onset of diarrhoea 3 days or more after
admission to hospital) accounted for the majority of cases,
but a sizeable percentage of CDI was community-acquired
(15 %). Substantial rates of CDI in the community are
probably related to a number of factors [23], and have
been recently reported in the literature [24].
As a major finding from our study is that CDI seems
associated with a worse outcome, with a three-time
higher in-hospital overall mortality vs no-CDI patients
(16.5 % vs 6.7 %), and in nearly half of cases (46 %) CDI
was considered related to patient death. Historically, the
attributable mortality of CDI was considered low (less
than 2 % of cases) [25]. However, consistent with our
findings, more recent literature has reported a marked
increase of CD-associated mortality and case-fatality
rates [11, 26, 27]. In addition, in our survey CDI was as-
sociated with a significantly longer (doubled) hospital
stay, thus confirming the high economic burden of this
infection [28].
Recurrence is one of the most important challenges in
the management of CDI. Our period of observation
(4 weeks after completion of antibiotic treatment for
CDI and actually around 6 weeks after diagnosis of CDI)
is somewhat shorter but quite similar to that indicated
by international guidelines to define the presence of re-
currence (8 weeks after the onset of a previous episode
of CDI) [2]. In our study, recurrence occurred in around
15 % of patients, mostly during the first 2 weeks of
follow-up. This recurrence rate is slightly lower than
some previous reports [9, 10], but still clinically relevant;
in this perspective, it will be interesting to see in the fu-
ture the impact, in real-life, of novel treatments for CDI
which have been associated with a lower risk of recur-
rence [10, 29, 30].
Most of the predisposing factors we found as signifi-
cantly related to CDI (positive history for the infection,
use of antibiotics, recent hospitalization, and age), are
consistent with those reported in previous studies [16].
In particular, antibiotic therapy is confirmed as a signifi-
cant predictor of CDI, though around one-third of our
patients affected with CD had a negative history for anti-
biotics. Our data suggest that clinical suspicion of diar-
rhoea from CDI should be driven not solely by the
presence of a current or recent antibiotic course. This point
is especially important in outpatients [31], who may be at
greater risk of underdiagnosis. Another unique finding of
our study was that females appeared at increased risk of
CDI, which has not been previously reported [32], and
required future confirmation. A trend towards higher
incidence of CDI has been observed in our study for
patients receiving proton-pump inhibitors. This item
has been addressed in several studies, and our data seem
to support the results of recent meta-analyses showing a
50 to 65 % increase in the incidence of CDI among pa-
tients on proton-pump inhibitors [33, 34]. However,
concerns have been raised on the quality evidence of
this association [35, 36], and further studies, preferably
prospective, are needed to fully explore the causative
relationship between proton-pump inhibitors and CD-
associated diarrhoea. A limitation of our study was that
we were not able to explore predictors of CDI recurrence
due to the relatively low number of cases with recurrent
CDI in our cohort.
A rapid and accurate laboratory diagnosis is crucial for
optimizing the prevention and management of CDI, and
many different approaches are available. However, the
most appropriate approach for diagnosis remains a topic
of debate, and very recent findings raised concern on
possible overdiagnosis rather than on under-recognition
of the infection [37]. Preferably a two- or three-stage al-
gorithm should be performed to diagnose CDI, in which
a positive first test is confirmed with one or two con-
firmatory tests or a reference method [2, 3]. In our ex-
perience, the two-step EIA method for detection of
C.difficile GDH and A and B toxins, showed a very high
specificity (more than 95 %); however, the percentage of
false negative for toxins among patients with positive
GDH was substantial, and largely corrected by a molecu-
lar method (the real-time PCR assay Xpert® C. difficile).
Our data support the value of a two-step algorithm
Fig. 3 Distribution of CD ribotypes identified in the study population
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including EIA GDH and toxins when both tests are
positive, and an additional molecular test (or toxigenic
culture) for toxins in case of GDH+/TOX– samples by
EIA.
The majority of strains isolated in this study belonged
to ribotype 018 or 356/607. These ribotypes are predom-
inant in Italy and are phylogenetically related [22, 38]. In
particular, infection by ribotype 018 is associated with
complicated CDI [16]. In the last several years, hypervir-
ulent strains 027 and 078 have become more prevalent
causes of CDI in Italy [22, 38–40]. In our study, none of
the ribotypes showed a significant correlation with ad-
verse outcome, probably due to the low number of
samples.
One potential strength of the FADOI-PRACTICE
study is its prospective design. This allowed a reliable
assessment of associated independent variables for
CDI, as well as a strict follow-up in patients with CD-
associated diarrhoea. Further, it was possible to sys-
tematically apply (in all cases with diarrhoea) the same
approach for laboratory diagnosis of CDI, along with a
post-hoc assessment for all GDH positive samples; to-
gether with the rigorous method for selection of par-
ticipating centers and the screening of the total
population of all patients admitted to IMUs, this rea-
sonably makes our findings of interest and accurate for
the specific study setting. On the other hand, as a pos-
sible limitation of our study, the 4-month enrolment
period may have obscured possible seasonal variations
in the occurrence of CDI, as previously reported [18].
In addition, no follow-up was scheduled for patients
with GDH+/Tox- samples, and since some of these pa-
tients were considered positive for CDI by the PCR
method, this could make our outcome results not
complete.
Conclusions
In conclusion, data from the FADOI-PRACTICE study
demonstrate that, on a nationwide basis, CDI is worth
considering and a potentially severe complication among
patients hospitalized in Italian Internal Medicine wards
(at least one case was detected in 29 out of the 40 par-
ticipating centers). This observation should lead clini-
cians to suspect CDI in presence of diarrhoea and risk
factors, and makes improvements in the surveillance
systems advisable. Clinicians should be aware of the
diagnostic algorithms, including their possible limita-
tions, utilized in the clinical microbiology laboratory of
their hospital. In this perspective, and based on a strict
cooperation between clinicians and clinical microbiolo-
gists, our survey supports the use of a 2–3 step algorithm
for diagnosis: enzyme immunoassay for detecting C.diffi-
cile GDH and A/B toxin, and a molecular method (e.g. a
real-time PCR assay) in case of toxin negative samples.
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